

8 September 2026

Immunoglobulin utilisation

I would like to submit a request under the Freedom of Information Act 2000 for the following data for Belfast Health and Social Care Trust covering [Q1 2026 (January, February, and March 2026)] and [Q2 2026 (April, May, and June 2026), referred to below as "the quarter."

1. IMMUNOGLOBULIN-TREATED PATIENTS BY INDICATION

For each of the following indications, please provide the number of unique patients treated with immunoglobulin (Ig) during the quarter:

- Primary Immunodeficiency (PID)
 - Secondary Immunodeficiency (SID)
 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- If possible, please segment each indication by Ig brand used (e.g., 5 patients on Cuvitru).

From MDSAS database:

	January to March 2026			April to June 2026		
	PID	SAD	CIDP	PID	SAD	CIDP
Gamunex	23	38	8	19	36	9
Octagam	<5	<5	<5	<5	<5	<5
Panzyga	18	24	6	17	24	6
Privigen	<5	6	<5	0	5	0
Kiovig	9	32	0	9	36	0
Intratect	7	12	0	7	14	0
Cutaquig	6	<5	0	23	13	0
Cuvitru	20	6	0	21	6	0
Hizentra PFS	<5	<5	0	<5	<5	0
Xembify	9	5	0	9	8	0
HyQvia	25	10	0	23	10	0
Total	117	133	14	128	152	

2. NEW STARTS

Of the Ig-treated patients in Question 1, how many were naïve patients (new starts, i.e., initiated Ig therapy for the first time) during the quarter, for each of PID, SID, and CIDP? If possible, by brand.

From MDSAS database:

January to June 2026			
	PID	SAD	CIDP
Gamunex	<5	0	0

8 September 2026

Octagam	0	0	<5
Panzyga	0	<5	<5
Kiovig	<5	12	0
Intratect	<5	<5	0
Cutaquig	<5	0	0
Xembify	0	<5	0
Total	8	19	5

3. TREATMENT STOPS

How many patients discontinued Ig therapy during the quarter (i.e., stopped treatment and were not switched to another Ig brand), for each of PID, SID, and CIDP? If possible, by brand stopped.

Under Section 1(1)(a) of the Freedom of Information Act 2000, the Trust can confirm that this information is not centrally held in recorded format.

4. BRAND SWITCHES

How many patients switched from one Ig brand to another during the quarter for each indication? If possible, please provide:

- The number of patients gained by each brand (switched TO)
- The number of patients lost by each brand (switched FROM)

If brand-to-brand pairs are readily available (e.g., 3 patients switched from Privigen to Hizentra), that would be appreciated but is not essential.

Between January to June 2026:

SAD – 1 patient switched from Privigen to Gamunex

SAD – 1 patient switched from Octagam to Panzyga

DEFINITIONS (ICD-10 codes for reference)

- PID: D80 (Immunodeficiency with predominantly antibody defects)
- SID: D84.81 (Immunodeficiency due to conditions classified elsewhere), D84.821 (due to drugs), D84.822 (due to external causes), D84.9 (unspecified)
- CIDP: G61.8 (Other inflammatory polyneuropathies)

Please note:

We are unable to provide an exact figure where numbers are very low. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.